Results 161 to 170 of about 679,692 (300)

Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
We systematically reviewed conversion therapy for esophageal squamous cell carcinoma and propose a response‐based treatment strategy for cT4b and M1 disease. For cT4b, we emphasize definitive chemoradiotherapy with timed re‐evaluation and selective salvage or chemoselection to surgery; for M1, conversion is reserved for limited‐burden responders with ...
Eisuke Booka, Hiroya Takeuchi
wiley   +1 more source

Minimally Invasive Esophagectomy for Esophageal Cancer: Current Evidence and Future Perspectives

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim Esophageal cancer is a highly aggressive malignancy with regional variations in histological subtypes. Adenocarcinoma predominates in Western countries, whereas squamous cell carcinoma is more common in Asia. Despite advances in multimodal therapy, esophagectomy remains the cornerstone of curative treatment, and the development of various ...
Hirotaka Konishi   +3 more
wiley   +1 more source

Revising Fascial Anatomy With a Focus on the Fusion Fascia in Mesenteric Gastrointestinal Cancer Surgery

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This review critically reassesses our prior hypothesis and proposes a revised anatomical model of the fusion fascia that is broadly applicable to GI cancer surgeries grounded in the principles of mesenteric resection. Our synthesis suggests that the fusion fascia is neither a dense connective tissue membrane nor a remnant of mesothelial fusion, but ...
Hisashi Shinohara   +9 more
wiley   +1 more source

Total Neoadjuvant Therapy for Rectal Cancer: Why Japan Says “Not Yet”

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Total neoadjuvant therapy (TNT) has rapidly gained global acceptance as a standard treatment for locally advanced rectal cancer (LARC). Supported by multiple phase III trials, TNT improves pathological complete response (pCR) rates, enhances systemic control, and expands opportunities for non‐operative management (NOM).
Kay Uehara   +4 more
wiley   +1 more source

Papillary Cystadenoma of Minor Salivary Glands: Report of 11 Cases and Review of the English Literature. [PDF]

open access: yesHead Neck Pathol, 2015
Tjioe KC   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy